➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
McKesson
Colorcon
Dow
Johnson and Johnson

Last Updated: October 23, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,750,711

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,750,711
Title:Low dose oral pharmaceutical composition of isotretinoin
Abstract: The present invention provides a low dose oral pharmaceutical composition of isotretinoin having reduced food effect, in particular no food effect. The present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention.
Inventor(s): Madan; Harish Kumar (Haryana, IN), Venkateshwaran; Rathinasabapathy (Tamil Nadu, IN), Madan; Sumit (Delhi, IN), Kochhar; Ravi (Haryana, IN)
Assignee: Sun Pharmaceutical Industries Limited (Mumbai, IN)
Application Number:15/444,571
Patent Claims: 1. An oral pharmaceutical composition in the form of a capsule comprising isotretinoin and a pharmaceutically acceptable excipient, wherein the composition has a mean C.sub.max value in the range of about 9 ng/mL/mg to about 40 ng/mL/mg when administered in a dose of about 0.4 mg/kg to about 1.6 mg/kg of the body weight in a human subjects under fasting conditions.

2. The oral pharmaceutical composition in the form of a capsule of isotretinoin according to claim 1 wherein the composition has AUC.sub.0-t in the range of about 125 ngh/mL/mg to about 500 ngh/mL/mg under fasting condition.

3. The oral pharmaceutical composition in the form of a capsule of isotretinoin according to claim 2 wherein composition exhibits mean fed/fasted ratio of AUC.sub.0-t value of about 0.9 to about 1.40.

4. The oral pharmaceutical composition in the form of a capsule composition according to claim 1 wherein the composition is in the form of a dispersion which is further filled into the capsules.

5. The oral pharmaceutical composition in the form of a capsule composition according to claim 1 wherein the isotretinoin is micronized and has D.sub.90 less than 30 .mu.m.

6. The oral pharmaceutical composition in the form of a capsule composition according to claim 1 wherein the isotretinoin is present in an amount of about 5.5% to about 15% based on the total weight of the composition.

7. The oral pharmaceutical composition in the form of a capsule composition according to claim 1 wherein the composition further comprises a surfactant.

8. The oral pharmaceutical composition in the form of a capsule composition according to claim 7 wherein the surfactant is selected from the group consisting of anionic, cationic or non-ionic surfactants, sorbitan fatty acid esters; polysorbates; mononylphenyl ethers of polyethyleneglycols; dioctyl sodium sulfosuccinate, sodium lauryl sulphate, lecithin, fatty acid esters of propylene glycol, fatty acid esters of glycerol, poloxamers, and mixtures thereof.

9. The oral pharmaceutical composition in the form of a capsule according to claim 1, wherein the composition releases not less than 50% of isotretinoin in 15 minutes when measured in United States Pharmacopeia (USP) type II dissolution apparatus, paddle at 75 rpm, in 900 mL of pH 7.4 phosphate buffer with 70 mg/L pancreatin and 4.5% LDAO as 30% solution with spiral coated sinker.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
AstraZeneca
Merck
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.